Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

A Patient’s Journey With Modern Melanoma Therapy

Black AC, Senofsky G. A Patient's Journey With Modern Melanoma Therapy. Cureus. 2025 Jun 26;17(6):e86811. doi: 10.7759/cureus.86811. PMID: 40718227; PMCID: PMC12296936.

Adjunctive Use of Electrical Stimulation (E-Stim) for Pain Relief and Rehabilitation in a Skilled Nursing Facility Patient Following Right Glenoid Fracture and Humeral Head Dislocation

Rodriguez Reyes DA, Kominami E, Kang J, Darouian N. Adjunctive Use of Electrical Stimulation (E-Stim) for Pain Relief and Rehabilitation in a Skilled Nursing Facility[...]

Navigating risk: Effect of counseling on contraception practice in urban Hispanic women with systemic lupus erythematosus

Stens O, Ruddy K, Rodman J, Wise L. Navigating risk: Effect of counseling on contraception practice in urban Hispanic women with systemic lupus erythematosus. Int[...]